Posts filtered by tags: US Food and Drug Administration for Simufilam[x]


 

Cassava Sciences jumps 16% on meeting with FDA paving the way for phase 3 study of Alzheimer's treatment

Westend61/ Shares of Cassava Sciences jumped as much as 16% on Monday on news that it successfully completed an end-of-phase two meeting with the FDA for its Alzheimer's treatment Simufilam. The biotech company will be moving forward with a pivotal phase-three study in the second half of this year.  Simufilam is a novel drug that targets "both neuroinflammation and neurodegeneration. Sign up here for our daily newsletter, 10 Things Before the Opening Bell Shares of Cassava Sciences jumped...
Tags: Trends, Markets, Alzheimer's Disease, Trading, Fda, Stock Market, Austin Texas, Alzheimer's Drugs, Isabelle Lee, Cassava Sciences, Remi Barbier, Simufilam, Opening Bell Shares of Cassava Sciences, US Food and Drug Administration for Simufilam, Rubicon Simufilam, Alzheimer s Association Shares of Cassava Sciences